Utmos

Pioglitazone

NIDDM type 2 as monotherapy or in combination w/ sulfonylurea, metformin or insulin w/ diet & exercise.

Initially 15 mg or 30 mg once daily. May be increased up to 45 mg increments once daily if response is inadequate.

May be taken with or without food.

Hypersensitivity.

Discontinue if signs & symptoms of heart eg, rapid wt gain, edema, dyspnea, or heart disease develop; deterioration of cardiac status occurs; ALT levels remain >3x ULN. New onset or worsening diabetic macular edema w/ decreased visual acuity. Not to be used in patients w/ severe degree of heart failure (established NYHA Class III or IV); active bladder cancer. Not recommended in patients w/ symptomatic heart failure. Patients w/ prior history of, or at risk of bladder cancer; hypoglycemia. Increased risk of edema; bladder cancer; CHF in patients w/ previously known heart disease. Anemia; wt gain associated w/ fluid retention; haematuria, urinary incontinence, dysuria, back or abdominal pain. Decreased Hb & hematocrit. Evaluate serum ALT levels prior to initiation of therapy & periodically thereafter. Regular eye exam w/ ophthalmologist. Not recommended in patients w/ hepatic disorders or abnormal liver function. Higher incidence of bone fracture in females w/ type 2 DM. Premenopausal women should use adequate contraception. Not recommended in pregnancy & lactation. Childn or adolescents <18 yr.

URTI, headache, sinusitis, myalgia, tooth disorder, aggravation of DM, pharyngitis; anemia; dyspnea, wt gain or edema; elevated creatinine phosphokinase; hypoglycemia.

Increased peak plasma conc & AUC w/ CYP3A4 inhibitors eg, ketoconazole. Reduced peak plasma conc & AUC w/ CYP3A4 substrates eg, atorvastatin, midazolam, ethinyl estradiol, nifedipine ER.

Antidiabetic Agents

A10BG03 - pioglitazone ; Belongs to the class of thiazolidinediones. Used in the treatment of diabetes.

S